ReviewClinical and experimental hepatology2026
Treatment of hepatitis C in children and adolescents: our experience to date, current status, and prospects.
Review in Clinical and experimental hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this review was to summarize previous Polish experience in treating hepatitis C virus (HCV) in children with direct-acting antivirals (DAAs) and to describe the current situation and perspectives for future HCV treatment in the pediatric cohort. Children aged at least 3 years were only included in the national Polish therapeutic HCV program on April 1, 2025. However, since 2018, over 200 children and adolescents have been treated with DAAs in noncommercial and commercial trials and real-life programs. Through the current therapeutic program, only adult dosages and formulations of DAAs are available; thus, younger children may not be included. They may, however, receive pediatric formulations donated courtesy of pharmaceutical companies. Screening programs, at least for children at risk of HCV infection, should be implemented to identify candidates for DAA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.